Ligand Pharmaceuticals Inc.
LGND
$284.47
-1.65%
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that develops and acquires technologies to aid in creating medicines, operating primarily through partnerships and license agreements with pharmaceutical and biotech firms. Its business model centers on drug discovery, early-stage development, and product reformulation, generating revenue from royalties, license and milestone payments, and sales of its Captisol material. As a leading biopharma royalty aggregator, Ligand has recently announced the acquisition of XOMA Royalty, a move expected to be immediately accretive to earnings and further solidify its market position. The current investor narrative focuses on this strategic acquisition, which is seen as accelerating profit growth and strengthening Ligand's portfolio of revenue-generating assets, while the stock has surged over 90% in the past year, reflecting optimism about its royalty-driven growth model.…
LGND
Ligand Pharmaceuticals Inc.
$284.47
Related headlines
LGND 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ligand Pharmaceuticals Inc.'s 12-month outlook, with a consensus price target around $342.82 and implied upside of +20.5% versus the current price.
Average Target
$342.82
0 analysts
Implied Upside
+20.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$247 - $390
Analyst target range
Ligand has coverage from 10 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.22). The average target price is $344.10, implying an upside of approximately 16.8% from the current price of $294.60. The distribution is bullish, with no sell ratings, and recent actions from firms like RBC Capital, B of A Securities, and Stifel have maintained or reiterated positive ratings. The high target of $390.00 suggests potential upside of 32.4%, while the low target of $247.00 implies a downside of 16.2%. The wide spread between high and low targets indicates significant uncertainty about the company's future, likely due to the lumpy nature of royalty income and the integration of the XOMA acquisition. The consensus leans strongly bullish, reflecting confidence in Ligand's growth strategy and accretive acquisitions.
Drowning in data?
Find the real signal!
Bulls vs Bears: LGND Investment Factors
Ligand presents a compelling bull case with strong revenue growth, high margins, and a strategic acquisition that could accelerate profit growth. However, the lumpy revenue stream and premium valuation introduce significant risk. Currently, the bull case has stronger evidence, given the accretive XOMA deal and robust analyst support. The key tension is whether the market's growth expectations (reflected in the 29x PE) can be met despite revenue volatility. If the acquisition delivers as promised and revenue stabilizes, the stock could re-rate higher; otherwise, valuation compression is likely.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 14.09% YoY to $51.72M, indicating solid top-line momentum. This growth is driven by royalty streams and the recent XOMA acquisition, which is expected to be immediately accretive.
- High Profitability Margins: Gross margin stands at 97.5% and net margin at 46.4%, reflecting the asset-light royalty model. This high profitability supports premium valuation and strong cash generation.
- Accretive XOMA Acquisition: The acquisition of XOMA Royalty is expected to be immediately accretive to earnings, strengthening Ligand's position as a leading biopharma royalty aggregator. This strategic move diversifies revenue and enhances growth prospects.
- Strong Analyst Consensus: With a Strong Buy rating (mean 1.22) and an average target price of $344.10, analysts see 16.8% upside. The high target of $390 implies 32.4% upside, reflecting confidence in the growth strategy.
Bearish
- Lumpy Revenue Stream: Quarterly revenue is highly volatile: Q3 2025 hit $115.46M, but Q1 2026 was only $51.72M. This lumpiness, driven by milestone payments, makes earnings unpredictable and complicates valuation.
- Premium Valuation: Trailing PE of 29.36x is 47% above the biotech industry average of ~20x. While justified by high margins, any growth disappointment could trigger multiple compression.
- Integration Risks: The XOMA acquisition brings integration risks, including potential operational disruptions or failure to realize expected synergies. This could weigh on near-term earnings.
- Recent Negative Earnings: Q1 2026 reported a net loss of -$13.35M and EPS of -$0.67, a sharp reversal from Q4 2025's profit. This volatility may concern investors seeking stable earnings.
LGND Technical Analysis
Ligand's stock is in a strong sustained uptrend, with a 1-year price change of +91.56%, significantly outperforming the S&P 500's +20.37% over the same period. The current price of $294.60 sits at approximately 90% of its 52-week range (low $149.51, high $326.63), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The stock's beta of 0.983 indicates volatility roughly in line with the market, providing some stability relative to its sharp price appreciation.
Beta
0.98
0.98x market volatility
Max Drawdown
-14.1%
Largest decline past year
52-Week Range
$162-$327
Price range past year
Annual Return
+70.3%
Cumulative gain past year
| Period | LGND Return | S&P 500 |
|---|---|---|
| 1m | -3.0% | -1.1% |
| 3m | +11.3% | +3.0% |
| 6m | +40.2% | +15.4% |
| 1y | +70.3% | +16.2% |
| ytd | +49.6% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LGND Fundamental Analysis
Ligand's revenue trajectory shows volatility but recent growth: Q1 2026 revenue was $51.72 million, up 14.09% year-over-year from $45.33 million in Q1 2025. However, quarterly revenue has fluctuated significantly, with Q3 2025 reaching $115.46 million, Q4 2025 at $59.67 million, and Q2 2025 at $47.63 million. The company's revenue is driven by royalties (e.g., $50.53 million in royalty revenue, including $40.70 million from intangible royalty assets) and contract revenue ($66.74 million), indicating a diversified but lumpy revenue stream. The growth trend is positive but uneven, reflecting the milestone-based nature of the business.
Quarterly Revenue
$51722000.0B
2026-03
Revenue YoY Growth
+14.1%
YoY Comparison
Gross Margin
96.0%
Latest Quarter
Free Cash Flow
$122956000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LGND Overvalued?
Given that Ligand's trailing twelve-month net income is positive (as of Q4 2025, net income was $44.78 million, and Q3 2025 was $117.27 million), the PE ratio is the primary valuation metric. The trailing PE is 29.36x, while the forward PE is 24.68x, implying the market expects earnings growth of about 19% over the next year. The PEG ratio is negative (-0.01), which is not meaningful due to the volatile earnings. Compared to the biotechnology industry average PE of around 20x, Ligand trades at a premium of approximately 47%, justified by its high gross margins (97.5%) and strong net margin (46.4%), reflecting its asset-light royalty model. Historically, Ligand's PE has ranged from negative (due to losses) to over 100x, and the current 29x is below its historical peaks, suggesting the market is pricing in moderate growth expectations.
PE
29.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include revenue volatility, as seen in quarterly swings from $115M to $47M, which complicates forecasting and may lead to earnings misses. The company's debt-to-equity ratio of 0.44 is moderate, but the negative EPS in Q1 2026 (-$0.67) highlights potential cash flow strain. High dependence on royalty income from a few key products could amplify downside if those products face competition or patent cliffs. The negative PEG ratio (-0.01) reflects unstable earnings, making traditional valuation metrics unreliable.
